Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience

Kandoth, 2013, the Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113 Hussein, 2018, Molecular insights into the classification of high-grade endometrial carcinoma, Gyneco Pathology, 50, 151 Bokhman, 1983, Two pathogenetic types of endometrial carcinoma, Gynecol Oncol, 15, 10, 10.1016/0090-8258(83)90111-7 Hecht, 2006, Molecular and pathologic aspects of endometrial carcinogenesis, J Clin Oncol, 24, 4783, 10.1200/JCO.2006.06.7173 Lax, 2000, The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways, Cancer, 88, 814, 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U Prat, 2004, Prognostic parameters of endometrial carcinoma, HumPathol, 35, 649 Lax, 2004, Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification, Virchows Arch, 444, 213, 10.1007/s00428-003-0947-3 Bansal, 2009, The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies, Cancer Control, 16, 8, 10.1177/107327480901600102 Alvarez, 2012, Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?, Am J Surg Pathol, 36, 753, 10.1097/PAS.0b013e318247b7bb Cirisano, 2000, The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma, Gynecol Oncol, 77, 55, 10.1006/gyno.2000.5737 Halperin, 2002, Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma: a clinicopathologic study, Eur J Gynaecol Oncol, 23, 300 Alektiar, 2002, Is there a difference in outcome between stage I–II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer?, Int J Radiat Oncol Biol Phys, 54, 79, 10.1016/S0360-3016(02)02913-9 Boruta, 2004, Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?, Cancer, 101, 2214, 10.1002/cncr.20645 Soslow, 2007, Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences, Am J Surg Pathol, 31, 979, 10.1097/PAS.0b013e31802ee494 Voss, 2012, Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer: a clinical and pathological evaluation, Gynecol Oncol, 124, 15, 10.1016/j.ygyno.2011.07.030 Van Driel W, Creutzberg C, Grimbergen C, et al.: National guideline ‘endometrial cancer’. Approved by the Dutch society of Obstetrics and Gynaecology (NVOG) in. February February 2011;2011. Cooke, 2011, Does the revised international federation of gynecology and obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes, Cancer, 117, 4231, 10.1002/cncr.26030 Hinshaw, 2013, The risk of subsequent malignancies in women with uterine papillary serous or clear cell endometrial cancers, Int J Gynecol Cancer, 23, 1044, 10.1097/IGC.0b013e3182959053 Creutzberg, 2000, Surgery and postoperative radiotherapy versus surgery alone for patients with, stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma, Lancet, 355, 1404, 10.1016/S0140-6736(00)02139-5 Sert, 2017, Evaluation of unusual and highly aggressive variant of endometrium cancer: nonendometrioid endometrium carcinoma of the uterus, Tumori, 103, 551, 10.5301/tj.5000404 Hamilton, 2006, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br J Cancer, 94, 642, 10.1038/sj.bjc.6603012 Cirisano, 2000, The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma, Gynecol Oncol, 77, 55, 10.1006/gyno.2000.5737 Boruta, 2004, Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?, Cancer, 101, 2214, 10.1002/cncr.20645 Voss, 2012, Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer: a clinical and pathological evaluation, Gynecol Oncol, 124, 15, 10.1016/j.ygyno.2011.07.030 McMeekin, 2007, Gynecologic Oncology Group study. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study, Gynecol Oncol, 106, 16, 10.1016/j.ygyno.2007.04.032 Greggi, 2011, Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study, Int J Gynecol Cancer May, 21, 661, 10.1097/IGC.0b013e3182150c89 Creasman, 2004, Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium, Gynecol Oncol, 95, 593, 10.1016/j.ygyno.2004.08.019 Fader, 2009, UPSC Consortium. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC), Gynecol Oncol, 115, 244, 10.1016/j.ygyno.2009.07.030 Ayeni, 2013, Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas, Gynecol Oncol, 129, 478, 10.1016/j.ygyno.2013.03.011 Soslow, 2007, Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences, Am J Surg Pathol, 31, 979, 10.1097/PAS.0b013e31802ee494 Reynaers, 2015, Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer, J Surg Oncol, 111, 790, 10.1002/jso.23871 Kim, 2013, A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system, J Gynecol Oncol, 24, 120, 10.3802/jgo.2013.24.2.120